Ozmosi | Polaprezinc Drug Profile

Product Description

Mechanisms of Action: HO1 Inducer

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: Australia | China | Korea

Approved Indications: None

Known Adverse Events: None

Company: ZERIA
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Taste Disorders

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
CTR20251497	CTR20251497	N/A	Completed	Healthy Volunteers	2025-06-02	2025-06-29	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
NCT06678997	GER	N/A	Not yet recruiting	Esophagitis, Peptic\|Gastroesophageal Reflux	2025-04-01	2024-11-08	Primary Endpoints\|Treatments
CTR20250777	CTR20250777	N/A	Completed	Healthy Volunteers	2025-03-23	2025-04-29	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
CTR20244758	CTR20244758	N/A	Completed	Healthy Volunteers	2025-01-16	2025-04-29	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
CTR20243088	CTR20243088	N/A	Completed	Healthy Volunteers	2024-12-07	2025-04-29	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
CTR20242711	CTR20242711	N/A	Completed	Healthy Volunteers	2024-11-14	2025-04-29	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
ChiCTR2300070469	ChiCTR2300070469	N/A	Not yet recruiting	Helicobacter Infections	2024-02-29	2023-06-09	Treatments
NCT05549778	PEACe	P2	Completed	Prostate Cancer	2023-01-20	2023-07-12	Patient Enrollment\|Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
ChiCTR1900028329	ChiCTR1900028329	N/A	Recruiting	Unknown	2022-12-31
ACTRN12620001188921	ToPaZ Study	P2	Completed	Digestive System Cancer\|Mouth Cancer\|Intestinal Diseases\|Liver Cancer\|Colorectal Cancer\|Lymphoma\|Gastrointestinal Cancer\|Leukemia\|Mucositis	2022-07-01	2025-10-31	Treatments
CTR20210011	CTR20210011	N/A	Completed	Healthy Volunteers	2021-01-13	2025-04-29	Patient Enrollment\|Primary Completion Date\|Study Completion Date\|Treatments\|Trial Status
CTR20202184	CTR20202184	N/A	Completed	Healthy Volunteers	2020-12-19	2025-04-29	Treatments
ChiCTR1900025800	ChiCTR1900025800	N/A	Not yet recruiting	Helicobacter Infections	2020-03-15
NCT02243618	NCT02243618	N/A	Completed	Gastrointestinal Cancer\|Adenoma	2016-04-14	2019-03-28	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
ChiCTR-IIR-16009688	ChiCTR-IIR-16009688	N/A	Completed	Gastritis\|Helicobacter Infections	2015-06-30
JapicCTI-121907	JapicCTI-121907	P3	Completed	Taste Disorders	2014-09-30
JapicCTI-111633	JapicCTI-111633	N/A	Completed	Other	2007-08-01
JapicCTI-050077	JapicCTI-050077	N/A	Unknown	Helicobacter Infections	2006-12-01
CTR20253588	CTR20253588	N/A	Terminated	Healthy Volunteers	None	2025-09-28	Treatments\|Trial Status
CTR20232872	CTR20232872	N/A	Not yet recruiting	Healthy Volunteers	None	2025-04-29	Patient Enrollment\|Treatments\|Trial Status
CTR20254274	CTR20254274	N/A	Not yet recruiting	Healthy Volunteers	None	2025-10-28	Treatments
CTR20243117	CTR20243117	N/A	Not yet recruiting	Healthy Volunteers	None	2025-04-29	Treatments\|Trial Status
CTR20253855	CTR20253855	N/A	Not yet recruiting	Healthy Volunteers	None	2025-09-23	Treatments
CTR20244559	CTR20244559	N/A	Not yet recruiting	Healthy Volunteers	None	2025-04-29	Patient Enrollment\|Treatments\|Trial Status
CTR20244281	CTR20244281	N/A	Not yet recruiting	Healthy Volunteers	None	2025-04-29	Patient Enrollment\|Treatments\|Trial Status

Recent News Events

Date	Type	Title
04/04/2024	PubMed	Expression analysis of zinc-metabolizing enzymes in the saliva as a new method of evaluating zinc content in the body: two case reports and a review of the literature.
04/02/2024	PubMed	Efficacy of Normalising Serum Zinc Level for Patients with Olfactory Dysfunction and Zinc Deficiency.
03/01/2024	PubMed	Zinc supplementation with polaprezinc was associated with improvements in albumin, prothrombin time activity, and hemoglobin in chronic liver disease.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Polaprezinc

Alternative Names: polaprezinc Clinical Status: Inactive Latest Update: 2024-11-07 Latest Update Note: Clinical Trial Update